Table 1 Patient characteristics

Age

Median

73

74

Range

57-100

57-92

Mean ± SD

72.93 ± 8.55

74.88 ± 7.79

TNM Stage

T0

1 (0.86%)

-

T1

6 (5.17%)

22 (27.16%)

T2

34 (29.31%)

30 (37.04%)

T3

62 (53.44%)

15 (18.52%)

T4

4 (3.45%)

1 (1.24%)

Metastases

2 (1.72%)

-

Gleason score

Median

7

5

Range

2-9

3-10

Initial PSA [ng/mL]

Median

19

10

Range

2-133

1-97

Mean ± SD

31.00 ± 8.67

12.46 ± 2.34

ADT

93 (80.07%)

33 (40.74%)

Previous surgery

RP

23 (19.83%)

22 (27.16%)

TURP

7 (6.03%)

5 (6.17%)

Therapy duration (m)

Median

57

54

Range

33-81

22-80

Mean ± SD

57.50 ± 5.56

54.04 ± 7.03

Recurrence Risk*

Low

1 (0.86%)

19 (23.46%)

Intermediate

20 (17.24%)

38 (46.91%)

High

94 (81.03%)

23 (28.40%)

Prescription dose (Gy)

≤ 71

60 (51.72%)

6 (7.41%)

72, 73

53 (45.69%)

72 (88.89%)

≥ 74

3 (2.59%)

3 (3.70%)

Disorders

Without complications

49 (42.24%)

37 (45.86%)

Cystoureteritis

16 (13.79%)

15 (18.52%)

Cystoureteritis + diarrhea

15 (12.93%)

1 (1.23%)

Proctocolitis + diarrhea

28 (24.14%)

14 (17.28%)

Unknown

8 (6.69%)

14 (17.28%)